With the Right Partner, Pfizer Gains Fast-Track Tag for Previously Shelved NASH Drug

In a rare win for the difficult field of nonalcoholic steatohepatitis (NASH) drug development, Pfizer has been granted a fast-track ticket for two experimental therapies.